Leading the way in Europe to bring microbiome-based innovations to market.
News
European court grants preliminary injunction against Pendulum and iHerb based on Caelus patent
DELFT, the Netherlands, 28 October 2026. The patent The claims of European patent EP 2 753 187 cover the use of a specific gut bacterium and protect a core application of Caelus’s platform. It stems from research at Amsterdam UMC and also covers the use of Caelus’s...
European Microbiome Innovation for Health (EMIH) brings together innovative leading European stakeholders dedicated to advancing the microbiome industry.
Our mission
The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.
About us
EMIH gathers more than 20 key private and public players supporting each other’s efforts to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
EMIH is collectively building a dynamic ecosystem to advance medical innovation centered on the microbiota, prioritizing public health within the EU and addressing unmet medical needs to enhance the quality of life for millions of patients.
Our members
EMIH brings together more than 30+ key private and public players committed to develop tomorrow’s medicine based on microbiome diagnostic and therapeutic innovations.
Join us!
Unity is strength. Joining EMIH means being able to provide input to policy makers, patients’ associations, investors in Europe, and share networking opportunities while contributing to structure the industry.
News
European court grants preliminary injunction against Pendulum and iHerb based on Caelus patent
> READ
Microbiotica Raises £36 Million ($48 Million) in Series C Financing to Advance Pipeline into Phase 2 Clinical Development
> READ
Caelus Receives a Positive EFSA Safety Opinion Under the EU Novel Food Regulation for its Pioneering Gut Bacterium
> READ